Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 8/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.48 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16076990 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL10171357 | 0.91 | GNAI3 (0.51) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL764586 | 0.91 | GNAI3 (0.51) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL16072733 | 0.85 | GNAI3 (0.68) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL16072734 | 0.85 | GNAI3 (0.68) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL16072731 | 0.80 | GNAI3 (0.59) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL16072732 | 0.75 | GNAI3 (0.51) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL10170348 | 0.75 | GNAI3 (0.67) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL754482 | 0.75 | GNAI3 (0.67) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL4731984 | 0.74 | HSP90AA1 (0.53) | MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | GNAI3 1106/4885GNAO1 212/4885GNAI1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.